{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:33:22Z","timestamp":1793835202641,"version":"4.6.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T00:00:00Z","timestamp":1522713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T00:00:00Z","timestamp":1522713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The computational repositioning of existing drugs represents an appealing avenue for identifying effective compounds to treat diseases with no FDA-approved pharmacotherapies. Here we present the largest meta-analysis to date of differential gene expression in human vestibular schwannoma (VS), a debilitating intracranial tumor, and use these data to inform the first application of algorithm-based drug repositioning for this tumor class. We apply an open-source computational drug repositioning platform to gene expression data from 80 patient tumors and identify eight promising FDA-approved drugs with potential for repurposing in VS. Of these eight, mifepristone, a progesterone and glucocorticoid receptor antagonist, consistently and adversely affects the morphology, metabolic activity, and proliferation of primary human VS cells and HEI-193 human schwannoma cells. Mifepristone treatment reduces VS cell viability more significantly than cells derived from patient meningiomas, while healthy human Schwann cells remain unaffected. Our data recommend a Phase II clinical trial of mifepristone in VS.<\/jats:p>","DOI":"10.1038\/s41598-018-23609-7","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T01:57:18Z","timestamp":1522288638000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Computational repositioning and preclinical validation of mifepristone for human vestibular schwannoma"],"prefix":"10.1038","volume":"8","author":[{"given":"Jessica E.","family":"Sagers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4393-1003","authenticated-orcid":false,"given":"Adam S.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasa","family":"Vasilijic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca M.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet I.","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas D.","family":"Landegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy H.","family":"Perlis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac S.","family":"Kohane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Bradley","family":"Welling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8756-8525","authenticated-orcid":false,"given":"Chirag J.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantina M.","family":"Stankovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,3]]},"reference":[{"key":"23609_CR1","doi-asserted-by":"publisher","first-page":"6216","DOI":"10.1038\/onc.2010.363","volume":"29","author":"KD Hadfield","year":"2010","unstructured":"Hadfield, K. D. et al. Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas. Oncogene 29, 6216\u20136221 (2010).","journal-title":"Oncogene"},{"key":"23609_CR2","doi-asserted-by":"publisher","first-page":"e46132","DOI":"10.1371\/journal.pone.0046132","volume":"7","author":"AR Asthagiri","year":"2012","unstructured":"Asthagiri, A. R. et al. Mechanisms of hearing loss in neurofibromatosis type 2. PLoS ONE 7, e46132 (2012).","journal-title":"PLoS ONE"},{"key":"23609_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/srep18599","volume":"5","author":"S Dilwali","year":"2015","unstructured":"Dilwali, S., Landegger, L. D., Soares, V. Y. R., Deschler, D. G. & Stankovic, K. M. Secreted factors from human vestibular schwannomas can cause cochlear damage. Sci. Rep. 5, 18599 (2015).","journal-title":"Sci. Rep."},{"key":"23609_CR4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/MAO.0000000000000239","volume":"35","author":"SR Plotkin","year":"2014","unstructured":"Plotkin, S. R., Merker, V. L., Muzikansky, A., Barker, F. G. & Slattery, W. Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients. Otol. Neurotol. 35, 50 (2014).","journal-title":"Otol. Neurotol."},{"key":"23609_CR5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/bib\/bbv020","volume":"17","author":"J Li","year":"2016","unstructured":"Li, J. et al. A survey of current trends in computational drug repositioning. Brief. Bioinformatics 17, 2\u201312 (2016).","journal-title":"Brief. Bioinformatics"},{"key":"23609_CR6","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1126\/science.1132939","volume":"313","author":"J Lamb","year":"2006","unstructured":"Lamb, J. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929\u201335 (2006).","journal-title":"Science"},{"key":"23609_CR7","doi-asserted-by":"publisher","first-page":"96ra77","DOI":"10.1126\/scitranslmed.3001318","volume":"3","author":"M Sirota","year":"2011","unstructured":"Sirota, M. et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci. Transl. Med. 3, 96ra77 (2011).","journal-title":"Sci. Transl. Med."},{"key":"23609_CR8","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/bioinformatics\/bts656","volume":"29","author":"C Pacini","year":"2013","unstructured":"Pacini, C. et al. DvD: An R\/Cytoscape pipeline for drug repurposing using public repositories of gene expression data. Bioinformatics 29, 132\u201334 (2013).","journal-title":"Bioinformatics"},{"key":"23609_CR9","doi-asserted-by":"publisher","first-page":"W449","DOI":"10.1093\/nar\/gku476","volume":"42","author":"Q Duan","year":"2014","unstructured":"Duan, Q. et al. LINCS Canvas Browser: interactive web app to query, browse and interrogate LINCS L1000 gene expression signatures. Nucleic Acids Res. 42, W449\u201360 (2014).","journal-title":"Nucleic Acids Res."},{"key":"23609_CR10","doi-asserted-by":"crossref","unstructured":"Musa, A., et al. A review of connectivity map and computational approaches in pharmacogenomics. Brief. Bioinform. bbw12 (2017).","DOI":"10.1093\/bib\/bbw112"},{"key":"23609_CR11","doi-asserted-by":"publisher","first-page":"96ra76","DOI":"10.1126\/scitranslmed.3002648","volume":"3","author":"JT Dudley","year":"2011","unstructured":"Dudley, J. T. et al. Computational repositioning of the anticonvulsant topimarate for inflammatory bowel disease. Sci. Transl. Med. 3, 96ra76 (2011).","journal-title":"Sci. Transl. Med."},{"key":"23609_CR12","unstructured":"Deftereos, S. N. Is a single type of data sufficient for computational drug repositioning? eLetters to Sci. Transl. Med. (2011): commentary on Dudley, J.T. et al (2011)."},{"key":"23609_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-016-0931-y","volume":"17","author":"AS Brown","year":"2016","unstructured":"Brown, A. S., Kong, S. W., Kohane, I. S. & Patel, C. J. ksRepo: a generalized platform for computational drug repositioning. BMC Bioinformatics 17, 78 (2016).","journal-title":"BMC Bioinformatics"},{"key":"23609_CR14","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1093\/nar\/gku935","volume":"43","author":"AP Davis","year":"2015","unstructured":"Davis, A. P. et al. The comparative toxicogenomics database\u2019s 10th year anniversary: update 2015. Nucleic Acids Res. 43, 914 (2015).","journal-title":"Nucleic Acids Res."},{"key":"23609_CR15","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1093\/nar\/gkj067","volume":"34","author":"DS Wishart","year":"2006","unstructured":"Wishart, D. S. et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 34, 668 (2006).","journal-title":"Nucleic Acids Res."},{"key":"23609_CR16","doi-asserted-by":"publisher","first-page":"848","DOI":"10.3892\/ijo.2013.1798","volume":"42","author":"M Torres-Martin","year":"2013","unstructured":"Torres-Martin, M. et al. Microarray analysis of gene expression in vestibular schwannomas reveals SPP1\/MET signaling pathway and androgen receptor deregulation. Int. J. Oncol. 42, 848\u2013862 (2013).","journal-title":"Int. J. Oncol."},{"key":"23609_CR17","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.3171\/2014.6.JNS131433","volume":"121","author":"S Agnihotri","year":"2014","unstructured":"Agnihotri, S. et al. Gene-expression profiling elucidates molecular signaling networks that can be therapeutically targeted in vestibular schwannoma. J. Neurosurg. 121, 1434\u20131445 (2014).","journal-title":"J. Neurosurg."},{"key":"23609_CR18","first-page":"2385","volume":"34","author":"JH Check","year":"2014","unstructured":"Check, J. H., Wilson, C., Cohen, R. & Sarumi, M. Evidence that mifepristone, a progesterone receptor antagonist, can cross the blood brain barrier and provide palliative benefits for glioblastoma multiforme grade IV. Anticancer Res. 34, 2385\u20132388 (2014).","journal-title":"Anticancer Res."},{"key":"23609_CR19","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1007\/s00701-014-2188-4","volume":"156","author":"M Touat","year":"2014","unstructured":"Touat, M., Lombardi, G., Farina, P., Kalamarides, M. & Sanson, M. Successful treatment of multiple intracranial meningiomas with the antiprogesterone receptor agent mifepristone (RU486). Acta Neurochir (Wien) 156, 1831\u20131835 (2014).","journal-title":"Acta Neurochir (Wien)"},{"key":"23609_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1016-4","volume":"15","author":"M Segovia-Mendoza","year":"2015","unstructured":"Segovia-Mendoza, M. et al. Antihormonal agents as a strategy to improve the effect of chemo-radiation in cervical cancer: in vitro and in vivo study. BMC Cancer 15, 21 (2015).","journal-title":"BMC Cancer"},{"key":"23609_CR21","doi-asserted-by":"publisher","first-page":"5215","DOI":"10.1158\/1078-0432.CCR-03-0637","volume":"10","author":"VT Gaddy","year":"2004","unstructured":"Gaddy, V. T. et al. Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells. Clin. Cancer Res. 10, 5215\u20135225 (2004).","journal-title":"Clin. Cancer Res."},{"key":"23609_CR22","first-page":"1047","volume":"29","author":"BT Moe","year":"2009","unstructured":"Moe, B. T., Vereide, A. B., Orbo, A., Jaeger, R. & Sager, G. Levonorgestrel, medroxyprogesterone and progesterone cause a concentration-dependent reduction in endometrial cancer (Ishikawa) cell density, and high concentrations of progesterone and mifepristone act in synergy. Anticancer Res. 29, 1047\u20131052 (2009).","journal-title":"Anticancer Res."},{"key":"23609_CR23","first-page":"999","volume":"12","author":"FV Rose","year":"1996","unstructured":"Rose, F. V. & Barnea, E. R. Response of human ovarian carcinoma cell lines to antiprogestin mifepristone. Oncogene 12, 999\u20131003 (1996).","journal-title":"Oncogene"},{"key":"23609_CR24","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/pros.2990260405","volume":"26","author":"MF Lin","year":"1995","unstructured":"Lin, M. F., Kawachi, M. H., Stallcup, M. R., Grunberg, S. M. & Lin, F. F. Growth inhibition of androgen-insensitive human prostate carcinoma cells by a 19-norsteroid derivative agent, mifepristone. Prostate 26, 194\u2013204 (1995).","journal-title":"Prostate"},{"key":"23609_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-207","volume":"11","author":"CR Tieszen","year":"2011","unstructured":"Tieszen, C. R., Goyeneche, A. A., Brandhagen, B. N., Ortbahn, C. T. & Telleria, C. M. Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression. BMC Cancer 11, 207 (2011).","journal-title":"BMC Cancer"},{"key":"23609_CR26","first-page":"623","volume":"30","author":"JH Check","year":"2010","unstructured":"Check, J. H., Dix, E., Cohen, R., Check, D. & Wilson, C. Efficacy of the progesterone receptor antagonist mifepristone for palliative therapy of patients with a variety of advanced cancer types. Anticancer Res. 30, 623\u2013628 (2010).","journal-title":"Anticancer Res."},{"key":"23609_CR27","first-page":"2413","volume":"34","author":"JH Check","year":"2014","unstructured":"Check, J. H., Check, D., Cohen, R. & Sarumi, M. Mifepristone causing complete remission of rapidly advancing leukemia with measurement of progesterone-induced blocking factor. Anticancer Res. 34, 2413\u20132416 (2014).","journal-title":"Anticancer Res."},{"key":"23609_CR28","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1080\/07357900601062339","volume":"24","author":"SM Grunberg","year":"2006","unstructured":"Grunberg, S. M. et al. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest. 24, 727\u2013733 (2006).","journal-title":"Cancer Invest."},{"key":"23609_CR29","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.molonc.2015.03.009","volume":"9","author":"S Dilwali","year":"2015","unstructured":"Dilwali, S. et al. Preclinical validation of anti-nuclear factor kappa B therapy to inhibit human vestibular schwannoma growth. Molecular Oncology 9, 1359\u20131370 (2015).","journal-title":"Molecular Oncology"},{"key":"23609_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trsl.2014.12.007","volume":"166","author":"S Dilwali","year":"2015","unstructured":"Dilwali, S., Kao, S., Fujita, T., Landegger, L. D. & Stankovic, K. M. Nonsteroidal anti-inflammatory medications are cytostatic against human vestibular schwannomas. Transl. Res. 166, 1\u201311 (2015).","journal-title":"Transl. Res."},{"key":"23609_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-35","volume":"13","author":"BN Brandhagen","year":"2013","unstructured":"Brandhagen, B. N. et al. Cytostasis and morphological changes induced by mifepristone in human metastatic cancer cells involve cytoskeletal filamentous actin reorganization and impairment of cell adhesion dynamics. BMC Cancer 13, 35 (2013).","journal-title":"BMC Cancer"},{"key":"23609_CR32","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1097\/nen.0b013e318093e555","volume":"66","author":"C Flaiz","year":"2007","unstructured":"Flaiz, C., Kaempchen, K., Matthies, C. & Hanemann, C. O. Actin-rich protrusions and nonlocalized GTPase activation in merlin-deficient schwannomas. J. Neuropathol. Exp. Neurol. 66, 608\u2013616 (2007).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"23609_CR33","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1042\/bj3560377","volume":"356","author":"MF James","year":"2001","unstructured":"James, M. F., Manchanda, N., Gonzalez-Agosti, C., Hartwig, J. H. & Ramesh, V. The neurofibromatosis 2 protein product merlin selectively binds F-actin but not G-actin, and stabilizes the filaments through a lateral association. Biochem. J. 356, 377\u2013386 (2001).","journal-title":"Biochem. J."},{"key":"23609_CR34","first-page":"5","volume":"2","author":"T Denayer","year":"2014","unstructured":"Denayer, T., St\u00f6hr, T. & Van Roy, M. Animal models in translational medicine: Validation and prediction. New Horizons in Translational Medicine 2, 5\u201311 (2014).","journal-title":"New Horizons in Translational Medicine"},{"key":"23609_CR35","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1747-5341-4-2","volume":"4","author":"N Shanks","year":"2009","unstructured":"Shanks, N., Greek, R. & Greek, J. Are animal models predictive for humans? Philos. Ethics Humanit. Med. 4, 2 (2009).","journal-title":"Philos. Ethics Humanit. Med."},{"key":"23609_CR36","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/10937404.2010.483176","volume":"13","author":"D Krewski","year":"2010","unstructured":"Krewski, D. et al. Toxicity testing in the 21st century: a vision and a strategy. J Toxicol. Environ. Health B. Crit. Rev. 13, 51\u2013138 (2010).","journal-title":"J Toxicol. Environ. Health B. Crit. Rev."},{"key":"23609_CR37","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.heares.2014.05.006","volume":"315","author":"S Dilwali","year":"2014","unstructured":"Dilwali, S. et al. Primary culture of human Schwann and schwannoma cells: improved and simplified protocol. Hear. Res. 315, 25\u201333 (2014).","journal-title":"Hear. Res."},{"key":"23609_CR38","first-page":"e55827","volume":"124","author":"LD Landegger","year":"2017","unstructured":"Landegger, L. D. et al. A unified methodological framework for vestibular schwannoma research. J Vis Exp 124, e55827 (2017).","journal-title":"J Vis Exp"},{"key":"23609_CR39","doi-asserted-by":"publisher","first-page":"4093","DOI":"10.1200\/JCO.2015.61.6490","volume":"33","author":"Y Ji","year":"2015","unstructured":"Ji, Y. et al. Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. J. Clin. Oncol. 33, 4093\u20134098 (2015).","journal-title":"J. Clin. Oncol."},{"key":"23609_CR40","doi-asserted-by":"publisher","first-page":"16981","DOI":"10.18632\/oncotarget.4858","volume":"6","author":"RL Beauchamp","year":"2015","unstructured":"Beauchamp, R. L. et al. A high-throughput kinome screen reveals serum\/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. Oncotarget 6, 16981\u201316997 (2015).","journal-title":"Oncotarget"},{"key":"23609_CR41","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/MAO.0000000000000189","volume":"35","author":"CK Kandathil","year":"2014","unstructured":"Kandathil, C. K. et al. Aspirin intake correlates with halted growth of sporadic vestibular schwannoma in vivo. Otol. Neurotol. 35, 353\u2013357 (2014).","journal-title":"Otol. Neurotol."},{"key":"23609_CR42","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1097\/MAO.0000000000001180","volume":"37","author":"CK Kandathil","year":"2016","unstructured":"Kandathil, C. K., Cunnane, M. E., McKenna, M. J., Curtin, H. D. & Stankovic, K. M. Correlation between aspirin intake and reduced growth of human vestibular schwannoma: volumetric analysis. Otol. Neurotol. 37, 1428\u20131434 (2016).","journal-title":"Otol. Neurotol."},{"key":"23609_CR43","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/00129492-200305000-00018","volume":"24","author":"A Aronzon","year":"2003","unstructured":"Aronzon, A., Ruckenstein, M. J. & Bigelow, D. C. The efficacy of corticosteroids in restoring hearing in patients undergoing conservative management of acoustic neuromas. Otol. Neurotol. 24, 465\u2013468 (2003).","journal-title":"Otol. Neurotol."},{"key":"23609_CR44","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1124\/jpet.105.084145","volume":"315","author":"A Arora","year":"2005","unstructured":"Arora, A. & Scholar, E. M. Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther. 315, 971\u2013979 (2005).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"23609_CR45","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1083\/jcb.200703010","volume":"177","author":"M Curto","year":"2007","unstructured":"Curto, M., Cole, B. K., Lallemand, D., Liu, C. & McClatchey, A. I. Contact-dependent inhibition of EGFR signaling by Nf2\/Merlin. J. Cell Biol. 177, 893\u2013903 (2007).","journal-title":"J. Cell Biol."},{"key":"23609_CR46","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1097\/MAO.0b013e3181eb328a","volume":"31","author":"SR Plotkin","year":"2010","unstructured":"Plotkin, S. R. et al. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol. Neurotol. 31, 1135\u20131143 (2010).","journal-title":"Otol. Neurotol."},{"key":"23609_CR47","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/lary.22392","volume":"122","author":"A Jacob","year":"2012","unstructured":"Jacob, A. et al. Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas. Laryngoscope 122, 174\u2013189 (2012).","journal-title":"Laryngoscope"},{"key":"23609_CR48","unstructured":"Welling, D. B. Exploratory evaluation of AR-42 histone deacetylase inhibitor in the treatment of vestibular schwannoma and meningioma. ClinicalTrials.gov; identifier #NCT02282917 (2017)."},{"key":"23609_CR49","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1097\/MLG.0b013e318177e20b","volume":"118","author":"AK Patel","year":"2008","unstructured":"Patel, A. K., Alexander, T. H., Andalibi, A., Ryan, A. F. & Doherty, J. K. Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors. Laryngoscope 118, 1458\u20131463 (2008).","journal-title":"Laryngoscope"},{"key":"23609_CR50","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1017\/S0022215107000229","volume":"122","author":"S Cafer","year":"2008","unstructured":"Cafer, S. et al. Expression and clinical significance of Ki-67, oestrogen and progesterone receptors in acoustic neuroma. J. Laryngol. Otol. 122, 125\u2013127 (2008).","journal-title":"J. Laryngol. Otol."},{"key":"23609_CR51","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1055\/s-0028-1096198","volume":"18","author":"DM Dalgorf","year":"2008","unstructured":"Dalgorf, D. M., Rowsell, C., Bilbao, J. M. & Chen, J. M. Immunohistochemical investigation of hormone receptors and vascular endothelial growth factor concentration in vestibular schwannoma. Skull Base 18, 377\u2013384 (2008).","journal-title":"Skull Base"},{"key":"23609_CR52","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1477-5751-8-9","volume":"8","author":"S Jaiswal","year":"2009","unstructured":"Jaiswal, S., Agrawal, V., Jaiswal, A. K., Pandey, R. & Mahapatra, A. K. Expression of estrogen and progesterone receptors in vestibular schwannomas and their clinical significance. J. Negat. Results Biomed. 8, 9 (2009).","journal-title":"J. Negat. Results Biomed."},{"key":"23609_CR53","unstructured":"Cushing, H. Tumors of the nervus acusticus and the syndrome of the cerebellopontile angle (WB Saunders, 1917)."},{"key":"23609_CR54","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1055\/s-0034-1370784","volume":"75","author":"KJ Shah","year":"2014","unstructured":"Shah, K. J. & Chamoun, R. B. Large vestibular schwannomas presenting during pregnancy: management strategies. J. Neurol. Surg. B. Skull Base 75, 214\u2013220 (2014).","journal-title":"J. Neurol. Surg. B. Skull Base"},{"key":"23609_CR55","doi-asserted-by":"crossref","unstructured":"Goutagny, S. & Kalamarides, M. Medical treatment in neurofibromatosis type 2. Review of the literature and presentation of clinical reports. Neurochirurgie (2017).","DOI":"10.1016\/j.neuchi.2016.09.004"},{"key":"23609_CR56","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1200\/JCO.2015.64.3817","volume":"34","author":"JO Blakeley","year":"2016","unstructured":"Blakeley, J. O. et al. Efficacy and biomarker study of bevacizumab for hearing loss resulting from neurofibromatosis type 2-associated vestibular schwannomas. J. Clin. Oncol. 34, 1669\u20131675 (2016).","journal-title":"J. Clin. Oncol."},{"key":"23609_CR57","doi-asserted-by":"publisher","first-page":"e59941","DOI":"10.1371\/journal.pone.0059941","volume":"8","author":"FP Nunes","year":"2013","unstructured":"Nunes, F. P. et al. Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients. PLoS ONE 8, e59941 (2013).","journal-title":"PLoS ONE"},{"key":"23609_CR58","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s00280-014-2456-2","volume":"73","author":"KM Slusarz","year":"2014","unstructured":"Slusarz, K. M., Merker, V. L., Muzikansky, A., Francis, S. A. & Plotkin, S. R. Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients. Cancer Chemother. Pharmacol. 73, 1197\u20131204 (2014).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"23609_CR59","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1093\/nar\/gks1193","volume":"41","author":"T Barrett","year":"2013","unstructured":"Barrett, T. et al. NCBI GEO: archive for functional genomics data sets\u2013update. Nucleic Acids Res. 41, 991 (2013).","journal-title":"Nucleic Acids Res."},{"key":"23609_CR60","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"23609_CR61","unstructured":"Development Core Team R. R: A language and environment for statistical computing. Vienna, Austria: the R Foundation for Statistical Computing (2011)."},{"key":"23609_CR62","doi-asserted-by":"crossref","unstructured":"Friedman, H. Simplified determinations of statistical power, magnitude of effect and research sample sizes. Educ Psychol Meas (1982).","DOI":"10.1177\/001316448204200214"},{"key":"23609_CR63","unstructured":"Lumley, T. rmeta: Meta-analysis. R package (2009)."},{"key":"23609_CR64","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/bioinformatics\/btg405","volume":"20","author":"L Gautier","year":"2004","unstructured":"Gautier, L., Cope, L., Bolstad, B. M. & Irizarry, R. A. affy\u2013analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20, 307\u2013315 (2004).","journal-title":"Bioinformatics"},{"key":"23609_CR65","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/biostatistics\/4.2.249","volume":"4","author":"RA Irizarry","year":"2003","unstructured":"Irizarry, R. A. et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249\u2013264 (2003).","journal-title":"Biostatistics"},{"key":"23609_CR66","unstructured":"Carlson, M. org.Hs.eg.db: Genome wide annotation for human https:\/\/bioconductor.org\/packages\/release\/data\/annotation\/html\/org.hs.eg.db.html (2016)."},{"key":"23609_CR67","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.mrfmmm.2007.07.015","volume":"637","author":"P Lepont","year":"2008","unstructured":"Lepont, P. et al. Point mutation in the NF2 gene of HEI-193 human schwannoma cells results in the expression of a merlin isoform with attenuated growth suppressive activity. Mutat. Res. 637, 142\u2013151 (2008).","journal-title":"Mutat. Res."},{"key":"23609_CR68","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/sj.bjp.0707372","volume":"152","author":"M Lew","year":"2007","unstructured":"Lew, M. Good statistical practice in pharmacology: problem 2. Br. J. Pharmacol. 152, 299\u2013303 (2007).","journal-title":"Br. J. Pharmacol."},{"key":"23609_CR69","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","volume":"30","author":"A Kr\u00e4mer","year":"2014","unstructured":"Kr\u00e4mer, A., Green, J., Pollard, J. Jr. & Tugendreich, S. Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics 30, 523\u201330 (2014).","journal-title":"Bioinformatics"}],"updated-by":[{"DOI":"10.1038\/s41598-018-36016-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T00:00:00Z","timestamp":1542931200000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23609-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23609-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23609-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T03:57:19Z","timestamp":1671595039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23609-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,3]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["23609"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-23609-7","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41598-018-36016-9","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,3]]},"assertion":[{"value":"12 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2018","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"5437"}}